VORICONAZOLE-MEDIS voriconazole 50mg tablet blister pack

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

voriconazole, Quantity: 50 mg

Disponibbli minn:

Medis Pharma Pty Ltd

INN (Isem Internazzjonali):

Voriconazole

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; macrogol 3350

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

56, 10, 2, 30, 28, 50, 14, 20, 100

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

VORICONAZOLE-MEDIS is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation. This brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Sommarju tal-prodott:

Visual Identification: white, round biconvex tablets, debossed 'VC50' on one side and plain on the reverse; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2015-02-02